Skip to main content
Year archive

Swedish Orphan Biovitrum — 2023 filings

All 48 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2023, sourced directly from the official regulator.

48 Filings
2023 Period
2023 filings (48)
Filing Released Lang
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2023-11-30 Swedish
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Share Issue/Capital Change
2023-11-30 English
Sobi has completed the issuances of series C shares
Share Issue/Capital Change
2023-11-01 English
Sobi har genomfört en emission av C-aktier
Share Issue/Capital Change
2023-11-01 Swedish
Sobi emitterar C-aktier för att fullgöra sina åtaganden under utestående incitamentsprogram
Share Issue/Capital Change
2023-10-31 Swedish
Sobi issues series C shares to fulfil its obligations under outstanding incentive programmes
Share Issue/Capital Change
2023-10-31 English
Earnings Release 2023
Earnings Release Q3 2023
2023-10-30 Swedish
Earnings Release 2023
Earnings Release Q3 2023
2023-10-30 English
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2023-09-29 English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2023-09-29 Swedish
Sobi offentliggör slutligt utfall i företrädesemissionen
Capital/Financing Update
2023-09-19 Swedish
Sobi publishes the final outcome of the rights issue
Capital/Financing Update
2023-09-19 English
Sobi offentliggör preliminärt utfall i företrädesemissionen
Capital/Financing Update
2023-09-18 Swedish
Sobi publishes the preliminary outcome of the rights issue
Capital/Financing Update
2023-09-18 English
Sobi publishes prospectus regarding the rights issue
Capital/Financing Update
2023-08-28 English
Sobi offentliggör prospekt avseende företrädesemissionen
Report Publication Announcement
2023-08-28 Swedish
Sobi beslutar om en företrädesemission om cirka 6 024 miljoner SEK
Capital/Financing Update
2023-08-22 Swedish
Sobi resolves on a rights issue of approximately SEK 6,024 million
Capital/Financing Update
2023-08-22 English
Kommuniké från Swedish Orphan Biovitrums (Sobi) extra bolagsstämma
AGM Information
2023-08-15 Swedish
Bulletin from Swedish Orphan Biovitrum (Sobi)’s Extraordinary General Meeting (EGM)
AGM Information
2023-08-15 English
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information
2023-07-18 English
Kallelse till extra bolagsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information
2023-07-18 Swedish
Sobi intends to carry out a rights issue of approximately SEK 6,000 million and calls for an Extraordinary General Meeting to be held on 15 August 2023
Share Issue/Capital Change
2023-07-18 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Q2 2023
2023-07-18 Swedish
Earnings Release 2023
Earnings Release Q2 2023
2023-07-18 English
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2023-06-30 English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2023-06-30 Swedish
Sobi har framgångsrikt slutfört uppköpserbjudandet avseende samtliga utestående stamaktier i CTI BioPharma Corp.
M&A Activity
2023-06-24 Swedish
Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
M&A Activity
2023-06-24 English
Sobi inleder ett uppköpserbjudande avseende samtliga utestående stamaktier i CTI BioPharma Corp.
M&A Activity
2023-05-25 Swedish
Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
M&A Activity
2023-05-25 English
Sobi to acquire CTI BioPharma Corp. enhancing Sobi’s position in rare haematology
M&A Activity
2023-05-10 English
Sobi avser att förvärva CTI BioPharma Corp. – stärker Sobis position inom sällsynt hematologi
M&A Activity
2023-05-10 Swedish
Bulletin from Swedish Orphan Biovitrum (Sobi)’s Annual General Meeting (AGM)
AGM Information
2023-05-09 English
Kommuniké från Swedish Orphan Biovitrums (Sobi) årsstämma
AGM Information
2023-05-09 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-04-27 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-04-27 English
Sobi to streamline nirsevimab contractual arrangements
Capital/Financing Update
2023-04-09 English
Sobi renodlar avtalet för nirsevimab
M&A Activity
2023-04-09 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-04-03 Swedish
Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information
2023-03-30 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information
2023-03-30 Swedish
Fas 3-programmet DISSOLVE med SEL-212 vid kronisk gikt uppnår primära effektmått
Earnings Release FY 2023
2023-03-21 Swedish
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
Earnings Release FY 2023
2023-03-21 English
Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A
Earnings Release FY 2023
2023-03-02 English
Positiva topline-resultat från den pivotala fas 3-studien XTEND-Kids med efanesoctocog alfa hos barn under tolv år med hemofili A
Regulatory Filings
2023-03-02 Swedish
Earnings Release 2022
Earnings Release Q4 2022
2023-02-08 Swedish
Earnings Release 2022
Earnings Release Q4 2022
2023-02-08 English